Abstract
Overview
Introduction
Datamonitor expects the antihypertensive market to exceed $40bn by 2015 across
the seven major markets, with novel treatments and the market-leading ARBs
delivering much of this value. However, significant hurdles exist, and
pharmaceutical companies need to carefully design marketing campaigns and
pricing structures for their products.
Scope
- Event-driven sales forecasts, for the period 2006-2015, for the US, Japan,
France, Germany, Italy, Spain and the UK, plus a global overview
- Discussion of individual products in four main classes; beta blockers
(BBs), CCBs, ACE inhibitors and the ARBs
- Profiles of the country and market specific issues which will impact
future sales in the market including generic erosion and new product launches
- Commercial impact case studies on R&D innovation, clinical trial data and
European healthcare reform
Highlights
The growth rate of the antihypertensive market is declining. These changes
reflect the challenges faced by pharmaceutical companies over the next decade,
as brand erosion and healthcare reforms impact heavily. The slow and declining
growth rate does not reflect a stationary market, but the battle between the
drugs that make up the market
Cozaar's patent expiry in the US has the potential to alter the structure of
the antihypertensive market dramatically. Threats of generic substitution and
money-saving healthcare strategies which have plagued other markets are now
approaching the successful ARB class, and will have an impact on the whole
antihypertensive market.
Large pharmaceutical companies that have established themselves in the
cardiovascular arena are steering away from development in the
antihypertensives market. While still continuing to enjoy large revenues from
its cardiovascular arm, the research and development of Novartis shows that it
is now investing elsewhere.
Reasons to Purchase
- Quantify the future size and scope of the hypertension market and the
potential for new products
- Analyze options to expand commercial potential through pursuit of new
indications
- Formulate successful launch strategies to succeed in a highly competitive
market
View Cart
